Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study
- 1 May 1985
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 28 (5) , 490-495
- https://doi.org/10.1002/art.1780280504
Abstract
We evaluated the effect of the calcium channel blocking agent, nifedipine, on esophageal dysfunction in 15 patients with progressive systemic sclerosis, using a double‐blind, randomized, crossover, placebo‐controlled manometric study. Nifedipine significantly decreased lower esophageal sphincter pressure in these patients; this reduced lower esophageal sphincter pressure may cause gastroesophageal reflux. Thus, nifedipine may have detrimental effects on progressive systemic sclerosis patients.This publication has 49 references indexed in Scilit:
- Nifedipine treatment for Raynaud's phenomenonArthritis & Rheumatism, 1984
- Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's PhenomenonNew England Journal of Medicine, 1983
- Mechanism of Action of Calcium-Channel-Blocking AgentsNew England Journal of Medicine, 1982
- Mechanisms of Gastroesophageal Reflux in Patients with Reflux EsophagitisNew England Journal of Medicine, 1982
- Abnormalities of Pulmonary Vascular Dynamics and Inflammation In Early Progressive Systemic SclerosisArthritis & Rheumatism, 1981
- Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazemThe American Journal of Cardiology, 1980
- Morphologic Changes in the Digital Arteries of Patients with Progressive Systemic Sclerosis (Scleroderma) and Raynaud PhenomenonMedicine, 1980
- Esophageal motility in progressive systemic sclerosis (PSS)Digestive Diseases and Sciences, 1979
- Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction.Circulation, 1976
- Oesophageal changes in systemic sclerosis.Gut, 1966